Fig. 3

Hemocompatibility and immune activity of RuPOP@CM in vitro. Microscopy image of red blood cells treated with (A) RuPOP, (B) RuPOP@MCM and (C) RuPOP@KCM for 6 h. D Hemolysis detection of RuPOP, RuPOP@MCM and RuPOP@KCM. E The content of RuPOP in plasma versus time after intravenous injection of RuPOP and RuPOP@MCM. Pharmacokinetic index (F) K10, (G) MRT (H) CL of RuPOP, RuPOP@MCM, and RuPOP@KCM. Cytokine levels of (I) TNF-α, (J) IL-6, and (K) IL-12 in serum from mice after being treated with RuPOP, RuPOP@MCM and RuPOP@KCM for 24 h, 48 h, and 72 h respectively (n = 5 mice per group). L Scheme illustration of activated immune activity induced by RuPOP@MCM